clopidogrel and Bone Loss, Osteoclastic

clopidogrel has been researched along with Bone Loss, Osteoclastic in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	2 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Arnett, TR; Brandao-Burch, A; Hajjawi, M; Jorgensen, NR; Orriss, IR; Patel, JJ; Schwarz, P; Syberg, S	1
Collins, L; Conley, PB; Craft, CS; Deng, H; Eagleton, MC; Floyd, DH; Grabowska, D; Heller, E; Hirbe, AC; Hughes, A; Hurchla, MA; Novack, DV; Piwnica-Worms, D; Rogers, M; Schneider, JG; Steinberg, TH; Su, X; Townsley, S; Uluckan, O; Weilbaecher, KN; Wu, K; Xiang, J; Zou, W	1

Other Studies

2 other study(ies) available for clopidogrel and Bone Loss, Osteoclastic

Article	Year
Clopidogrel (Plavix), a P2Y12 receptor antagonist, inhibits bone cell function in vitro and decreases trabecular bone in vivo. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2012, Volume: 27, Issue:11 Topics: Alkaline Phosphatase; Animals; Azo Compounds; Biomarkers; Bone and Bones; Bone Density; Bone Resorption; Cell Count; Cell Survival; Cells, Cultured; Clopidogrel; Collagen; Cyclic AMP; Gene Expression Regulation; Intracellular Space; Mice; Osteoblasts; Osteoclasts; Osteogenesis; Purinergic P2Y Receptor Antagonists; Radiography; Receptors, Purinergic P2Y12; Solubility; Staining and Labeling; Ticlopidine	2012
The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling. The Journal of clinical investigation, 2012, Volume: 122, Issue:10 Topics: Adenosine Diphosphate; Animals; Arthritis, Experimental; Bone Neoplasms; Bone Remodeling; Bone Resorption; Carcinoma; Cell Adhesion; Cells, Cultured; Clopidogrel; Enzyme Activation; Female; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C57BL; Mice, Knockout; Osteoclasts; Osteoporosis; Ovariectomy; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2Y Receptor Antagonists; rap1 GTP-Binding Proteins; Receptors, Purinergic P2Y12; Specific Pathogen-Free Organisms; Ticlopidine	2012

Article

Year

Clopidogrel (Plavix), a P2Y12 receptor antagonist, inhibits bone cell function in vitro and decreases trabecular bone in vivo.

Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2012, Volume: 27, Issue:11

Topics: Alkaline Phosphatase; Animals; Azo Compounds; Biomarkers; Bone and Bones; Bone Density; Bone Resorption; Cell Count; Cell Survival; Cells, Cultured; Clopidogrel; Collagen; Cyclic AMP; Gene Expression Regulation; Intracellular Space; Mice; Osteoblasts; Osteoclasts; Osteogenesis; Purinergic P2Y Receptor Antagonists; Radiography; Receptors, Purinergic P2Y12; Solubility; Staining and Labeling; Ticlopidine

2012

The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling.

The Journal of clinical investigation, 2012, Volume: 122, Issue:10

Topics: Adenosine Diphosphate; Animals; Arthritis, Experimental; Bone Neoplasms; Bone Remodeling; Bone Resorption; Carcinoma; Cell Adhesion; Cells, Cultured; Clopidogrel; Enzyme Activation; Female; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C57BL; Mice, Knockout; Osteoclasts; Osteoporosis; Ovariectomy; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Purinergic P2Y Receptor Antagonists; rap1 GTP-Binding Proteins; Receptors, Purinergic P2Y12; Specific Pathogen-Free Organisms; Ticlopidine

2012